Article and Video CATEGORIES
Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Can SCLC also be treated with targeted therapy?
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.
Recent Comments
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on